Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Coherus Biosciences. The associated price target remains the same with $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors, including evidence that the weak first-quarter results were driven largely by temporary external issues rather than structural demand problems. Management indicated that severe winter storms and normal seasonality disrupted treatment cycles for existing patients, while underlying demand, as reflected in new patient starts, continued to strengthen and likely better represents the true growth trajectory.
Tsao also emphasizes the strong commercial momentum for Loqtorzi, highlighted by record new patient initiations, expanding use in community oncology settings, and increasing treatment duration, all supporting management’s outlook for double-digit quarterly demand growth and rising revenue targets through 2028. In addition, Loqtorzi’s status as the only approved PD-1 therapy in nasopharyngeal carcinoma, combined with targeted commercial initiatives to shift prescribing behavior away from chemo-only regimens and off-label competitors, underpins confidence in the company’s long-term revenue potential, justifying a reiterated Buy rating and an unchanged $7 price target.
According to TipRanks, Tsao is a 5-star analyst with an average return of 20.4% and a 50.50% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Xenon, Protagonist Therapeutics, and Disc Medicine.
In another report released yesterday, Guggenheim also initiated coverage with a Buy rating on the stock with a $12.00 price target.